




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/55, 9/16, 47/12</b>	A2	(11) International Publication Number: <b>WO 99/12549</b>
		(43) International Publication Date: 18 March 1999 (18.03.99)

(21) International Application Number: PCT/GB98/02692	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 7 September 1998 (07.09.98)	
(30) Priority Data: 9718986.4 9 September 1997 (09.09.97) GB	
(71) Applicant (for all designated States except US): DANBIOSYST UK LTD. [GB/GB]; Albert Einstein Centre, Highfields Science Park, Nottingham NG7 2TN (GB).	
(72) Inventors; and	
(75) Inventors/Applicants (for US only): ILLUM, Lisbeth [DK/GB]; 19 Cavendish Crescent North, The Park, Nottingham NG7 1BA (GB). CHENG, Yu-Hui [CN/GB]; 74A Dennis Avenue, Beeston, Nottingham NG9 2PR (GB). WATTS, Peter, James [GB/GB]; Flat 2, 47 Highfield Road, West Bridgford, Nottingham NG2 6DR (GB). DAVIS, Stanley, Stewart [GB/GB]; 19 Cavendish Crescent North, The Park, Nottingham NG7 1BA (GB).	
(74) Agent: BASSETT, Richard; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).	

(54) Title: CONTROLLED RELEASE MICROSPHERE DELIVERY SYSTEM



## (57) Abstract

There is provided a pharmaceutical composition comprising polymeric microparticles including a drug and a fatty acid, which composition may be adapted to provide a release rate of drug that is approximately linear with time, and to provide no significant burst effect.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## CONTROLLED RELEASE MICROSHERE DELIVERY SYSTEM

### **Field of the Invention**

This invention relates to a new drug delivery composition comprising  
5 biodegradable microspheres and/or microcapsules, which are useful, in  
particular, in the parenteral delivery of drugs.

### **Background to the Invention**

Olanzapine is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]-  
10 benzodiazepine. It is a serotonin (5-HT<sub>2</sub>) and dopamine (D<sub>1</sub>/D<sub>2</sub>) receptor  
antagonist with anticholinergic activity. The preparation of olanzapine has  
been described in US 5,229,382 (which document is hereby incorporated  
by reference). The comparative pharmacology of the compound has been  
reviewed by N. A. Moore *et al*, Curr. Opin. Invest. Drugs 2, 281 (1993).  
15 The drug is currently marketed as an oral tablet formulation that is taken  
on a daily basis.

The encapsulation of drugs into polymeric microspheres is a well  
established technology, which has been described in various reviews and  
20 books (e.g. Deasy, Microencapsulation and Related Drug Processes,  
Dekker, New York, 1987 and Chasin and Langer, Biodegradable  
Polymers as Drug Delivery Systems, Dekker, New York, 1990). A wide  
variety of drugs have been incorporated into polymers such as polylactide  
coglycolide, including low molecular weight conventional drugs, as well  
25 as peptides and proteins. The purpose of encapsulation is normally to  
provide a sustained or controlled release of a therapeutic agent or an  
antigen.

Microencapsulation processes based on emulsification and solvent removal are well known in the art (US 3,523,906, US 3,523,907, US 3,960,757).

In US 3,691,090, an organic solvent is evaporated from a dispersion of microparticles contained in an aqueous medium.

5

US 4,389,330 and US 4,530,840 describe the preparation of microparticles containing an active agent. The active agent and wall-forming agent are dissolved in a common solvent. The solution is then dispersed in a suitable non-miscible medium such as water. The solvent is 10 then evaporated to form microparticles containing the active agent. The final residual solvent can be removed by an extraction process. The particles can be of sizes ranging from below 1 to 100  $\mu\text{m}$  or larger. These prior art documents do not mention the use of a fatty acid in the formulation of controlled release microparticle systems.

15

The use of polylactide coglycolide materials for the controlled delivery of neuroleptic agents has been described for drugs such as haloperidol (WO 94/10982), resperidone (WO 95/13814) and fluphenazine (Ramtoola *et al* J. Microencaps. 2, 415 (1992)). The encapsulation of chlorpromazine in polylactide has been described by Suzuki and Price. J. Pharm. Sci. 74, 21 (1985). Sustained release microspheres containing antipsychotic agents are disclosed in Chem. Abs. 121(6) Abstract 65597, by Shigeni *et al*. However, none of these references disclose formulations comprising a fatty acid.

25

The use of carboxylic acid salt surfactants as emulsifiers in oil in water emulsions used for the preparation of microspheres with a particulate core formed from biodegradable polymers such as polylactide and poly(lactide coglycolide) has been described in the prior art, e.g. US 4,384,975 and

Fong *et al*, J. Controlled Release 1, 119, (1986). In these articles the drug was dispersed in a polymer solution (comprising an organic solvent) and an aqueous solution (containing sodium oleate or potassium oleate as an emulsifier). However, the use of free fatty acids as a component of the 5 microspheres is neither mentioned nor suggested.

In the conditions for which drugs such as olanzapine find utility, such as schizophrenia, patient compliance is of vital importance. It is often observed that patients refuse to take oral medication for reasons associated 10 with the symptoms of their condition. To improve patient compliance, it would therefore be of benefit to develop long acting e.g. intramuscular formulations of such drugs. In this respect, it is thus expected that a controlled release formulation of drugs such as olanzapine for intramuscular or subcutaneous administration, which provided steady 15 plasma levels of drug, would be advantageous, especially if such a formulation were capable of providing a steady, yet sufficiently high, level of drug to enable practical control of the disease.

It is well known that the encapsulation of a drug such as olanzapine into a 20 microsphere formulation in high quantities may give rise to an initial high release of drug (i.e. a burst effect). (Indeed, the applicants have confirmed this to be the case in experimentation (see below).) Such a burst effect may result in unacceptable side effects, including problems 25 associated with toxicity of the drug and (for drugs such as olanzapine) sedation.

Surprisingly, we have now discovered that a novel microparticle formulation comprising a drug (e.g. a basic drug, such as the neuroleptic drug, olanzapine), a polymer, such as polylactide coglycolide, and a fatty

acid, can be prepared, and may provide a formulation which produces little to no burst effect, as well as zero order release of drug over extended time periods.

5 We have found that, when a simple technique, such as an oil in water emulsification procedure, is employed to incorporate drugs such as olanzapine into polymeric (e.g. polylactide coglycolide) microparticles, without the presence of a fatty acid, an unacceptable burst effect is produced. Conversely, we have found that microparticulate compositions 10 including fatty acids, basic drugs (and, more particularly, neuroleptic agents) in biodegradable polymeric microparticles, not only improve the loading of drug into the microparticles, but may also provide a minimal initial burst of drug, and an approximate (i.e. substantially) linear release of drug. Such compositions have not been described in, or suggested by, 15 the prior art.

### **Description of the Invention**

According to the invention there is provided a pharmaceutical composition 20 comprising polymeric microparticles including a drug mixed with a fatty acid (referred to hereinafter as “the compositions of the invention”).

The compositions of the invention may, in particular, comprise biodegradable and/or biocompatible microparticles containing a basic 25 drug, more particularly a neuroleptic drug, such as a thienolbenzodiazepine (e.g. olanzapine), and a fatty acid.

We prefer that the drug is a weak base. By “weak base”, we include compounds with a pKa of less than 10.5.

The compositions of the invention may be prepared by dispersing drug and fatty acid in a polymer solution, using standard surfactant aqueous solutions as emulsifiers.

5

In particular, the compositions of the invention may preferably be produced by emulsification of a solution of a biodegradable polymer and fatty acid that will provide a wall forming material or matrix material. In such a procedure, the polymer and the fatty acid are first dissolved in a 10 suitable organic solvent and then dispersed as an oil in water emulsion in an aqueous environment, or as an oil-in-oil emulsion in a non-aqueous environment. Solid particles can be produced by a suitable process such as solvent evaporation or spray drying wherein the organic solvent is removed.

15

Drugs that are suitable for use in the compositions of the invention include, but are not limited to, neuroleptics such as thienolbenzodiazepines (e.g. olanzapine), benzodiazepines such as cromazepam, clobazam, diazepam, phenothiazines such as acetophenazine maleate, bromperidol, 20 respiridone, chlorpromazine, chlorprothixene, haloperidol, fluphenazine, fluspirilene, sex hormones such as danazol.

25

The term "neuroleptic" will be well understood by those skilled in the art (see, for example, Martindale, "*The Extra Pharmacopoeia*", 31st Edition, Royal Pharmaceutical Society (1996) at page 669 *et seq* and Dorland's Illustrated Medical Dictionary, 28th Edition, W. B. Saunders (1994) at page 110). The term most preferably refers to a compound selected from the group consisting of haloperidol, clozapine, respiridone, amisulpride, Seroquel® (quetiapine), sertindole, ziprasidone, zotepine, and olanzapine.

The most preferred neuroleptic is olanzapine. The term "neuroleptic" includes both basic and acidic drugs; however basic, especially weakly basic, neuroleptics are preferred.

5 Particularly useful polymeric materials which may be used in the compositions of the invention include polylactide coglycolide (PLG). PLG can be obtained from known suppliers (for example Boehringer Ingelheim) in a range of molecular weights and molar ratios of polylactide to polyglycolide. PLG is preferred because of its established regulatory 10 status and the fact it degrades to materials that can enter the metabolic pool.

15 The ratio of lactide to glycolide may be from 85:15 or thereabouts, preferably 75:25 or thereabouts, and more preferably 50:50. A preferred molecular weight for PLG polymer materials is in the range of from about 20 4 to 50 kD as determined by the Mark Houwink Equation (MHE) and 20 to 150 kD as measured by gel permeation chromatography using polystyrene standards. When the characteristics of the polymer are given in terms of intrinsic viscosity, a preferred range is 0.2 to 1.2 dl/g.

20 Suitable fatty acids which may be employed in the compositions of the invention include compounds comprising a saturated or unsaturated, linear or branched, acyclic hydrocarbon chain containing one or more carboxyl group. A range of fatty acids, including those with chain lengths from C<sub>8</sub> 25 to C<sub>24</sub> may be used in the present invention; however chain lengths from C<sub>14</sub> to C<sub>20</sub> are preferred.

A preferred fatty acid is oleic acid. Commercially available oleic acid may consist mainly of octadec-9-enoic acid and also contains some stearic and

palmitic acids. Ricinoleic acid is another preferred material. Commercially available ricinoleic acid may consist mainly of 12-hydroxy-9-octadecenoic acid but also contains other fatty acids obtained from the hydrolysis of castor oil from which ricinoleic acid is derived.

5

Suitable concentrations of fatty acids in the compositions of the invention are in the range 1 to 50% w/w, (i.e. wt%, expressed as a percentage of the weight of the microparticle), preferably 5 to 30% w/w and most preferably 10 to 20% w/w. Suitable concentrations of polymer materials 10 in the compositions of the invention are in the range 5 to 98% w/w (wt%, expressed as a percentage of the weight of the microparticle), preferably 10 to 96% w/w and most preferably 20 to 90% w/w.

15 The compositions of the invention provide not only a high loading of the drug (greater than 10% w/w expressed as a percentage of the final formulation), but may also provide an approximate linear release of drug over, for example, 30 days or more *in vitro*, and may also provide no significant burst effect.

20 By "approximate linear release", we include that the release follows essentially zero order kinetics and a plot of release rate against time can be best represented by a straight line relation. Permissible deviations from that straight line are in the range 0 to 50%, preferably 0 to 25% and more preferably 0 to 10%, over the main part of release of the drug from the 25 composition following administration. In other words, by "approximate linear release", we include that the rate of release of drug is essentially constant over the main part of the time over which drug is released following administration. Permissible deviations from "constant" are in the range 0 to 50%, preferably 0 to 25% and more preferably 0 to 10%, at

any one time over the main part of release of the drug from the composition following administration. By "main part" of release of the drug, we mean the part between any initial burst which may occur e.g. during the first day following administration, and any "tailing off" of release which may occur at the end of release. The main part of the release will typically constitute at least 80%, preferably at least 90%, of the total time over which drug is released.

The term "no significant burst effect", includes that no more than 30%, preferably no more than 25%, more preferably no more than 23%, and especially no more than 20%, of the loaded drug is released in one day (i.e. the first day following administration), as measured in an *in vitro* dissolution test using, for example, phosphate buffered saline as the release medium (e.g. as described below).

15

Compositions of the invention may provide an approximately linear release of drug over time, and may provide no significant burst effect. Moreover, compositions of the invention may be readily adapted to provide an approximately linear release, and to provide no significant burst effect, in accordance with techniques such as those described hereinafter.

The compositions of the invention may be of a size range suitable for injection, such as between 1 and 500  $\mu\text{m}$ , preferably between 20 and 150  $\mu\text{m}$ , as measured by a suitable technique, such as laser diffraction.

The route of administration and release rate often dictate the preferred size of the microparticle. Similarly, the choice of polymer (e.g., in the case of PLG, in terms of the ratio of lactide to glycolide), and the molecular

weight of the polymer, can be employed to obtain different release rates of encapsulated material. Further, fatty acid content and choice of fatty acid can provide further control over release rates of encapsulated material.

- 5 The microparticles can be administered using methods known in the art. Most preferably, the microparticles can be administered parenterally.

As used herein, the term "microparticles" includes microspheres, microcapsules and the like. We use the term "microsphere" herein to 10 describe a particle where the drug is distributed throughout (e.g. uniformly in) the polymer matrix. We use the term "microcapsule" to describe a particle where the drug is contained (e.g. as crystals) in the core of the microparticle and the polymer acts as a coating or shell.

- 15 The properties of microspheres and microcapsules can be controlled by the choice of polymer, fatty acid and the quantity of drug to be encapsulated in the polymer particle.

Suitable dosing regimens for a particular drug can be determined readily 20 by a physician or the skilled artisan based on the patient's condition and the properties of the drug. For example, a preferred dosage for olanzapine is from about 1 to about 25 mg/kg. More preferably the dosage is from about 5 to about 10 mg/kg.

- 25 The compositions of the invention may be administered to a mammal in suitable dosage forms, in accordance with techniques, and *via* delivery devices, all of which are known to those skilled in the art. However, we prefer that the compositions of the invention are administered parenterally. By the term "parenteral administration", we include the delivery of the

composition by injection to a warm blooded animal by subcutaneous, intramuscular, intravenous, epidural or intrathecal routes or such methods as are known to the skilled artisan. The more preferred routes of administration are subcutaneous and intramuscular.

5

The compositions of the present invention may comprise polymeric biodegradable and biocompatible microparticles designed to provide an effective amount of the active ingredient (i.e. the drug; such as a neuroleptic) over an extended period of time. A preferred embodiment is 10 the administration of a single dose of the microparticles loaded with drug to release the drug over an extended period of time, thus avoiding the necessity of repeated injections.

The present invention provides the controlled delivery of a drug, such as a 15 neuroleptic, over a period ranging from 5 to 100 days depending on the microparticle system selected. A preferred embodiment provides release over the period from about 10 to about 50 days or more particularly over the period from about 20 to about 40 days. The duration of action can be controlled by appropriate choice of polymer, microsphere particle size, 20 fatty acid choice and drug loading. A further preferred embodiment is release over the period of from about 14 to about 30 days. By "about", we include plus or minus 5 (e.g. 2) days in respect of the lower limits of the above-quoted release period ranges, and plus or minus 10 (e.g. 5, preferably 2) days in respect of the upper limits of the above-quoted 25 release period ranges.

The wall forming or matrix polymer can be chosen from a range of materials known to those skilled in the art that includes polylactides, polyglycolic acid, copolymers of polylactide and polyglycolide,

polycaprolactones, polyalkanoic acids, (particularly mixtures of polyhydroxybutyrate and polyhydroxyvalerate), polyorthoesters, polyanhydrides. A preferred polymer is polylactide coglycolide (PLG) and a preferred ratio of lactide to glycolide is about 50:50. The molecular weight of the selected polymer will be chosen after considering the fatty acid to provide the required release rate. Suitable molecular weights for the polymers are in the range 2 to 100 kD. The preferred material (polylactide coglycolide) has a molecular weight (inherent viscosity) in the range of from 9 - 50 kD or thereabouts. A especially preferred molecular weight range is 25 kD or thereabouts.

The polymers can be used singularly or in combination. A preferred material is the copolymer polylactide coglyclide (PLG).

15 The microparticles may be produced by a suitable emulsification (oil in water) method followed by a solvent removal process, or other processes known to the skilled artisan. The solvents can include those that are non-miscible with aqueous environments and include ethylacetate, benzyl alcohol, dichloromethane and halogenated hydrocarbons. Preferred

20 solvents are dichloromethane and ethyl acetate. Other processes which may include spray drying, coacervation, solvent evaporation, heat and/or cooling congealing, supercritical fluid, and other methods recognised by the skilled artisan, may be used.

25 A preferred method for preparation of the microparticles is by emulsion solvent evaporation method. The drug, the fatty acid and the polymer (e.g. polylactide coglycolide (PLG)) are co-dissolved in an appropriate solvent, such as dichloromethane to form the oil phase. This oil phase is mixed with an aqueous solution containing an emulsifier, such as

12

polyvinyl alcohol, and emulsified. A stirrer may be used to assist the emulsification process. The emulsion may be stirred for up to 24 hours at room temperature for the solvent evaporation to take place. The microparticles may be collected by an appropriate means, such as centrifugation, washed with an appropriate solvent, such as water and dried (e.g. by freeze drying). The dried particles may be passed through sieves to collect a suitable size fraction.

10 The emulsion may be (and normally is) stabilised by a suitable emulsifying agent. Materials which may be employed to this end include polyvinyl alcohol, polyvinyl pyrrolidone, bile salts and non-ionic surfactants. A preferred emulsifier material is polyvinyl alcohol. A suitable concentration is from 0.25 to 7% w/v. A preferred concentration is from 1 - 3% w/v. The size of the resultant particle may be controlled by the 15 processing conditions including stirring rate, organic/aqueous phase volume ratios, size and shape of the processing containers.

20 A size range from 1 - 500  $\mu\text{m}$  is suitable for parenteral administration. A size in the range 20 to 150  $\mu\text{m}$ , e.g. 60 to 120  $\mu\text{m}$ , is preferred.

The solvent can be removed by evaporation or drying processes or solvent extraction to include the use of supercritical fluids.

25 The particles may be stored in a dried state and may be mixed with a suitable pharmaceutically acceptable diluent to aid administration. Such diluents include aqueous sodium carboxy methylcellulose solution, with and without stabilisers (such as surfactants (e.g. polysorbates)), sesame oil and migliol A12.

Fatty acids suitable for use in the compositions of the invention include oleic acid, linoleic acid, linolenic acid, ricinoleic acid, capric acid, elaidic acid, lauric acid, stearic acid, palmitic acid, arachidonic acid, docosanedioic acid and polyunsaturated fatty acids such as eicosapentanoic acid and docosahexanoic acid. Oleic acid is a preferred material. Hydroxylated fatty acids may also be employed. Ricinoleic acid (a hydroxylated fatty acid) is another preferred material.

The microparticles can be produced in a sterile form through aseptic processing or treated after preparation with gamma irradiation at a dose of 10 2 Mrad. or higher.

The loading of the drug in the compositions of the invention will be dependent on the physicochemical properties of the compound but for a 15 lipophilic material, a loading of 1 to 90% (i.e. wt%, expressed as a percentage of the weight of the microparticle) could be expected. By “lipophilic compound”, we include a compound with a partition coefficient as measured between 1-octanol and an aqueous buffer at pH 7.0 of more than 10. More preferably, the compositions of the invention 20 may contain from 1 to 50 wt% of active ingredient and most preferably from 10 - 35 wt% of active ingredient.

For the avoidance of doubt, the terms “drug” and “therapeutic agent” are intended herein to include drugs/agents which are suitable for use in the 25 treatment, and in the prevention, of disease.

The compositions of the invention may be used to treat/prevent diseases/conditions in mammalian patients depending upon the therapeutic agent(s) which is/are employed. For the above, non-exhaustive, lists of

14

drugs, diseases/conditions which may be mentioned include those against which the therapeutic agent(s) in question are known to be effective, and include those specifically listed for the drugs in question in Martindale, "The Extra Pharmacopoeia", 31st Edition, Royal Pharmaceutical Society 5 (1996). When the composition according to the invention comprises a neuroleptic drug, the present invention provides a method for treating a warm-blooded animal suffering from or susceptible to psychotic disorders by the parenteral administration of a composition according to the invention.

10

The used herein phrase "dissolution test" refers to methods familiar to the artisan.

15 The invention is illustrated, but in no way limited, by way of the following examples, in which:

Figure 1 shows the cumulative release of olanzapine from PLG (50/50; 9 kD) microspheres (particle size  $\leq$  250  $\mu\text{m}$ ) loaded with 28.6% olanzapine; 30.8% olanzapine/7.7% oleic acid; and olanzapine/15.4% oleic acid.

20

Figure 2 shows the cumulative release of olanzapine from PLG (50/50; 25 kD) microspheres (particle size  $\leq$  250  $\mu\text{m}$ ) loaded with 28.6% olanzapine; 30.8% olanzapine/7.7% oleic acid; and olanzapine/15.4% oleic acid.

25

Figure 3 shows the cumulative release of olanzapine from PLG (50/50; 9 kD and 25 kD) microspheres (particle size  $\leq$  250  $\mu\text{m}$ ) loaded with 30% olanzapine/15% oleic acid.

Figure 4 shows the cumulative release of olanzapine from PLG (50/50; 25 kD) microspheres (particle size  $\leq$  150  $\mu\text{m}$ ) loaded with 30% olanzapine and 15% of a range of fatty acids.

5 Figure 5 shows the *in vitro* release of olanzapine from PLG microspheres (particle size  $\leq$  150  $\mu\text{m}$ ) loaded with 30% olanzapine and 15% oleic acid.

10 Figure 6 shows the plasma concentration of olanzapine in a group of five beagle dogs over time, following administration of from PLG microspheres (particle size  $\leq$  150  $\mu\text{m}$ ) loaded with 30% olanzapine and 15% oleic acid.

#### Example 1

15 PLG microspheres (particle size  $\leq$  250  $\mu\text{m}$ ) loaded with 28.6% olanzapine without added fatty acid. (Comparative example to demonstrate that a simple formulation provides an unsatisfactory release profile.)

20 100 mg of olanzapine and 250 mg of PLG (50/50, 9 kD or 25 kD) were co-dissolved in 2 to 3 mL of dichloromethane to form an oil phase. The oil phase was dropped into 100 to 150 mL of cooled aqueous phase containing 1% polyvinyl alcohol (PVA) and emulsified at 1000 rpm. The resulting o/w emulsion was agitated continuously for 4 h at room temperature. The microspheres were collected by centrifugation, washed with water and freeze-dried. The dried particles were passed through a 25 250  $\mu\text{m}$  sieve to remove any large aggregation and stored in a desiccator at room temperature. Duplicate samples of drug-loaded PLG microspheres containing about 5 mg of olanzapine were accurately weighed and suspended in two separate 500 mL of pH 7.4 PBS solution. The solutions were incubated at 37°C and gently agitated for 1 minute, twice a day.

At suitable times following the start of the test, 5 mL of supernatant from each solution was removed and passed through a 0.2  $\mu\text{m}$  membrane filter into a screw top vial. Then 5 mL of fresh PBS solution was added to each solution. The samples were evaluated for drug content by a UV method at 5 a wavelength of 228 nm.

The results are shown in Figures 1 and 2. The cumulative release of olanzapine show that the drug is released rapidly from the formulation produced from PLG 50:50, 9 kD and 25 kD molecular weight without 10 added fatty acid. Such particles would not be suitable for administration to patients due to the high initial burst of drug.

#### Example 2

PLG microspheres (particle size  $\leq$  250  $\mu\text{m}$ ) loaded with 30.8% 15 olanzapine:7.7% w/w oleic acid

200 mg of olanzapine, 50 mg of oleic acid and 400 mg of PLG (50/50; 9 kD or 25 kD) were co-dissolved in 4 mL of dichloromethane to form an oil phase. The oil phase was dropped into 200 mL of cooled aqueous 20 phase containing 1% polyvinyl alcohol (PVA) and emulsified at 1000 rpm. The resultant o/w emulsion was agitated continuously for 4 h at room temperature. The microspheres were collected by centrifugation, washed with water and freeze-dried. The dried particles were passed through a 250  $\mu\text{m}$  sieve to remove any large aggregation and stored in a desiccator at 25 room temperature. The drug release behaviour of the microspheres was determined as in Example 1. Figures 1 and 2 show that the addition of oleic acid at 7.7% reduce the release rate of olanzapine.

Example 3

PLG microspheres (particle size  $\leq$  250  $\mu\text{m}$ ) loaded with 30.8% olanzapine/15.4% w/w oleic acid

5 200 mg of olanzapine, 100 mg of oleic acid and 350 mg of PLG (50/50; 9 kD or 25 kD) were co-dissolved in 4 mL of dichloromethane to form an oil phase. The oil phase was dropped into 200 mL of cooled aqueous phase containing 1% polyvinyl alcohol (PVA) and emulsified at 1000 rpm. The resultant o/w emulsion was agitated continuously for 4 h at room 10 temperature. The microspheres were collected by centrifugation, washed with water and freeze-dried. The dried particles were passed through a 250  $\mu\text{m}$  sieve to remove any large aggregation and stored in a desiccator at room temperature. The drug release behaviour of the microspheres was determined as in Example 1. Figures 1 and 2 show that the addition of 15 oleic acid at 15.4% w/w reduces the release rate of olanzapine. For the case of the polymer of molecular weight 25 kD there is almost no burst effect and the release profile is essentially linear over a 10 day period.

Example 4

20 PLG microspheres (particle size  $\leq$  250  $\mu\text{m}$ ) loaded with 30.8% olanzapine/15% oleic acid

A further experiment was conducted to show the effect of the nature of the polymer in drug release profile.

25

218 mg of olanzapine, 109 mg of oleic acid and 400 mg of PLG (50/50, 9 kD or 25 kD) were co-dissolved in 4 mL of dichloromethane to form an oil phase. The oil phase was dropped into 200 mL of cooled aqueous phase containing 1% polyvinyl alcohol (PVA) and emulsified at 1000 rpm.

The resultant o/w emulsion was agitated continuously for 4 h at room temperature. The microspheres were collected by centrifugation, washed with water and freeze dried. The dried particles were passed through a 150  $\mu\text{m}$  sieve to remove any large aggregation and stored in a desiccator at room temperature. The drug release behaviour was determined as in Example 1. The results in Figure 3 show that a linear release of olanzapine can be obtained using 15% oleic acid and PLG of a molecular weight of 25 kD.

10 Example 5

PLG microspheres (particle size  $\leq 150 \mu\text{m}$ ) loaded with 30% olanzapine and 15% in a range of fatty acids

The 109 mg of oleic acid as in Example 4 was replaced by a range of fatty acids (arachidonic acid, docosahexanoic acid, eicosapentanoic acid, linoleic acid, linolenic acid and ricinoleic acid). The preparation and drug release measurements were conducted as in Example 4. The molecular weight of the PLG polymer was 25 kD in all cases. The results shown in Figure 4 show that different release rates can be obtained by choice of different fatty acids. The essentially linear profile obtained for arachidonic acid, ricinoleic acid and linoleic acid appear to be advantageous.

25 Example 6

Evaluation of olanzapine microsphere *in vivo* using a dog model

A batch of olanzapine (4 g) for animal testing was prepared as described in Example 4. The polymer was PLG 50:50 of a molecular weight 25 kD. The particles were loaded with 30% w/w olanzapine using 15% w/w oleic

acid. The dissolution behaviour was measured as described in Example 1. The dissolution results are shown in Figure 5. An approximately linear release profile for olanzapine was obtained. An experiment was conducted to measure the quantity of intact olanzapine remaining in the 5 microspheres.

Samples of microspheres were removed from the dissolution medium at 7 and 14 days. The samples were freeze-dried and then assayed by HPLC using a validated method to determine the amount of intact olanzapine. 10 Table 1 provides details of the amount of olanzapine released into the dissolution medium at 7 and 14 days respectively and the quantity of olanzapine remaining in the microspheres as compared to the theoretical amount if the results were corrected for the amount released. It will be seen that all the unreleased olanzapine could be recovered intact from the 15 microspheres.

Table 1: Release and recovery of olanzapine from PLG microspheres.

Time 20 (days)	Olanzapine release (% of encapsulated)	Olanzapine remaining in microspheres theoretical(%)*	Olanzapine remaining in microspheres residual (by HPLC)
7	34.9	65.1	65.3
14	77.3	22.7	23.2

25 \*Calculated from the amount of olanzapine released into the dissolution medium and the olanzapine content of the microspheres at the start of dissolution testing.

20

The olanzapine microspheres were administered intramuscularly to a group of 5 beagle dogs. The microspheres were suspended in a dosing vehicle comprising 2% CMC and 0.15% Tween 80 using a 21 gauge needle. The dose of drug was 5 mg/kg. The plasma concentration of the drug was measured by a validated HPLC method. The results shown in Figure 6 demonstrate that a steady level of drug could be obtained in the required range of 10 - 20 mg/mL over a suitable time period.

**Claims**

1. A pharmaceutical composition comprising polymeric microparticles including a drug and a fatty acid.

5

2. A composition as claimed in Claim 1 adapted to provide a release rate of the drug that is approximately linear.

3. A composition as claimed in Claim 1 or Claim 2 adapted to provide 10 an initial release of drug as measured using a dissolution test employing phosphate buffered saline as the release medium of less than 25%.

4. A composition as claimed in any one of the preceding claims wherein the drug is a weak base.

15

5. A composition as claimed in any one of the preceding claims wherein the drug is a neuroleptic.

6. A composition as claimed in any one of the preceding claims 20 wherein the drug is olanzapine.

7. A composition as claimed in any one of the preceding claims wherein the polymer is a copolymer of polylactic acid and polyglycolic acid.

25

8. A composition as claimed in any one of the preceding claims wherein the fatty acid is oleic acid or ricinoleic acid.

22

9. A composition as claimed in any one of the preceding claims wherein the microparticles comprise 1 to 90% w/w of active agent.
10. A composition as claimed in any one of the preceding claims 5 wherein the size of the microparticles is from 1 to 500 microns.
11. A composition as claimed in Claim 10, wherein the size of the microparticles is in the range 20 to 150 microns.
- 10 12. A composition as claimed any one of the preceding claims wherein the microparticles contain from 1 to 50 wt % of active ingredient.
13. A composition as claimed in Claim 12 wherein the microparticles contain from 10 to 35 wt % of active ingredient.
- 15 14. A pharmaceutical formulation comprising a composition as claimed in any one of the preceding claims and a pharmaceutical carrier.
- 15 20 15. A process for the preparation of a composition according to any one of Claims 1 - 13 which comprises mixing the drug with a fatty acid and encapsulating or dispersing the complex in a polymer material.
- 25 16. A method for treating a warm-blooded animal suffering from or susceptible to a psychotic disorder which comprises the parenteral administration of a composition according to any one of Claims 1 - 13, or a formulation according to Claim 14, to such an animal.
17. The use of a composition according to according to any one of Claims 1 - 13 in the manufacture of a medicament for use in the treatment

23

of a warm-blooded animal suffering from or susceptible to a psychotic disorder.

18. A method for the treatment or prophylaxis of a disease which 5 comprises administration of a composition according to any one of Claims 1 to 13, or a formulation according to Claim 14, including an active ingredient which is effective against said disease, to a patient in need of such treatment or prophylaxis.

10 19. A method as claimed in Claim 18, wherein the disease is a psychotic disorder.

15 20. The use of a composition according to any one of Claims 1 to 13 in the manufacture of a medicament for the treatment or prophylaxis of a disease which comprises administration of said composition, including a therapeutic agent which is effective against said disease, to a patient in need of such treatment or prophylaxis.

20 21. A use as claimed in Claim 20, wherein the disease is a psychotic disorder.

1/6




Figure 1

2/6




Figure 2

3/6




Figure 3

4/6





Figure 4

5/6


Figure 5



6/6

Figure 6

Species: Beagle Dogs (n = 5)  
Dose: 5 mg/kg  
Route of Admin: IM






## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/55, 9/16, 47/12</b>		A3	(11) International Publication Number: <b>WO 99/12549</b>
			(43) International Publication Date: 18 March 1999 (18.03.99)
(21) International Application Number: PCT/GB98/02692		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 7 September 1998 (07.09.98)			
(30) Priority Data: 9718986.4 9 September 1997 (09.09.97) GB			
(71) Applicant (for all designated States except US): DANBIOSYST UK LTD. [GB/GB]; Albert Einstein Centre, Highfields Science Park, Nottingham NG7 2TN (GB).			
(72) Inventors; and		Published	
(75) Inventors/Applicants (for US only): ILLUM, Lisbeth [DK/GB]; 19 Cavendish Crescent North, The Park, Nottingham NG7 1BA (GB). CHENG, Yu-Hui [CN/GB]; 74A Dennis Avenue, Beeston, Nottingham NG9 2PR (GB). WATTS, Peter, James [GB/GB]; Flat 2, 47 Highfield Road, West Bridgford, Nottingham NG2 6DR (GB). DAVIS, Stanley, Stewart [GB/GB]; 19 Cavendish Crescent North, The Park, Nottingham NG7 1BA (GB).		With international search report.	
(74) Agent: BASSETT, Richard; Eric Potter Clarkson, Park View House, 58 The Ropewalk, Nottingham NG1 5DD (GB).		(88) Date of publication of the international search report: 6 May 1999 (06.05.99)	

(54) Title: CONTROLLED RELEASE MICROSPHERE DELIVERY SYSTEM



(57) Abstract

There is provided a pharmaceutical composition comprising polymeric microparticles including a drug and a fatty acid, which composition may be adapted to provide a release rate of drug that is approximately linear with time, and to provide no significant burst effect.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 98/02692

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K31/55 A61K9/16 A61K47/12

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 733 368 A (ELI LILLY) 25 September 1996 see the whole document ---	1-21
A	FR 2 491 351 A (STOLLE) 9 April 1982 cited in the application see claims see page 8, line 26 - line 28 ---	1-21
A	US 4 384 975 A (J.W.FONG) 24 May 1983 cited in the application see claims see column 6, line 66 - column 7, line 7 see example 8 ---	1-21
A	EP 0 669 128 A (YOSHITOMI) 30 August 1995 cited in the application see the whole document ---	1-21
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 February 1999

Date of mailing of the international search report

04/03/1999

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Scarpioni, U

**INTERNATIONAL SEARCH REPORT**

International Application No

PCT/GB 98/02692

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 454 436 A (LILLY) 30 October 1991 cited in the application see the whole document -----	1-21
1		

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/02692

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.:

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claims 16, 18 and 19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2.  Claims Nos.:

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3.  Claims Nos.:

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02692

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
EP 733368	A	25-09-1996			NONE
FR 2491351	A	09-04-1982	US	4389330 A	21-06-1983
			AT	384557 B	10-12-1987
			AT	399481 A	15-05-1987
			AU	543059 B	28-03-1985
			AU	7594281 A	22-04-1982
			BE	890638 A	05-04-1982
			CA	1142810 A	15-03-1983
			CH	648494 A	29-03-1985
			DE	3136606 A	16-06-1982
			DK	376381 A, B,	07-04-1982
			FI	813077 A, B,	07-04-1982
			GB	2088314 A, B	09-06-1982
			IE	51822 B	01-04-1987
			JP	1489865 C	07-04-1989
			JP	57093912 A	11-06-1982
			JP	63036290 B	19-07-1988
			NL	8104507 A	03-05-1982
			SE	453798 B	07-03-1988
			SE	8105897 A	07-04-1982
			ZA	8105441 A	28-07-1982
US 4384975	A	24-05-1983	CH	648217 A	15-03-1985
			DE	3121983 A	04-02-1982
			FR	2484281 A	18-12-1981
			GB	2077693 A, B	23-12-1981
			JP	57027128 A	13-02-1982
			US	4933105 A	12-06-1990
EP 669128	A	30-08-1995	DE	669128 T	14-03-1996
			GR	96300020 T	31-03-1996
			CA	2148823 A	26-05-1994
			ES	2077547 T	01-12-1995
			WO	9410982 A	26-05-1994
			US	5656299 A	12-08-1997
EP 454436	A	30-10-1991	AT	127804 T	15-09-1995
			AU	643267 B	11-11-1993
			AU	7518691 A	07-11-1991
			BG	61710 B	31-03-1998
			CA	2041113 A, C	26-10-1991
			CN	1056693 A, B	04-12-1991
			CS	9101168 A	17-12-1991
			DE	69112895 D	19-10-1995
			DE	69112895 T	07-03-1996
			DK	454436 T	13-11-1995
			ES	2078440 T	16-12-1995
			FI	911986 A	26-10-1991
			FI	971316 A	27-03-1997
			GR	3017877 T	31-01-1996
			HK	87596 A	24-05-1996
			HU	212416 B	28-06-1996
			HU	9500335 A	30-10-1995
			IE	68401 B	12-06-1996
			IL	97912 A	31-10-1995
			JP	2527860 B	28-08-1996
			JP	7089965 A	04-04-1995

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/02692

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 454436	A	LU 90009 A	31-01-1997
		LV 10262 A, B	20-10-1994
		MX 25502 A, B	01-10-1993
		NO 178766 B	19-02-1996
		PT 97446 A, B	31-01-1992
		SI 9110739 A	31-10-1997
		SK 279196 B	08-07-1998
		RU 2043992 C	20-09-1995
		US 5229382 A	20-07-1993